نتائج البحث - "Caroline Robert"

1

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006

المؤلفون: Peter Hersey, Jean-Jacques Grob, Blanca Homet Moreno, Omid Hamid, Erin Jensen, Tara C. Mitchell, Georgina V. Long, Jedd D. Wolchok, Ana Arance, Anthony M. Joshua, Matteo S. Carlino, Caroline Robert, Laurent Mortier, Jacob Schachter, Jeffrey S. Weber, F. Stephen Hodi, Adil Daud, Scott J. Diede, Antoni Ribas

المصدر: European journal of cancer (Oxford, England : 1990). 157

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91d36204dbb77dc73c57b42b2ef7e542Test
https://pubmed.ncbi.nlm.nih.gov/34571336Test

2

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

المساهمون: Intégrité du génome, ARN et cancer, Institut Curie [Paris]-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), University of Zurich, Robert, Caroline

المصدر: European journal of cancer (Oxford, England : 1990)
European Journal of Cancer
European Journal of Cancer, Elsevier, 2021, 144, pp.182-191. ⟨10.1016/j.ejca.2020.11.010⟩

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, [SDV]Life Sciences [q-bio], Immune-checkpoint inhibitors, Pembrolizumab, Gastroenterology, 0302 clinical medicine, Antineoplastic Agents, Immunological, Immune-related adverse events, Monoclonal, 80 and over, 1306 Cancer Research, Melanoma, Humanized, Cancer, Aged, 80 and over, Clinical Trials as Topic, 10177 Dermatology Clinic, Middle Aged, Prognosis, Advanced melanoma, 3. Good health, Immunological, Oncology, 030220 oncology & carcinogenesis, 6.1 Pharmaceuticals, Toxicity, Public Health and Health Services, 2730 Oncology, Female, PD-1 inhibitors, Adult, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Oncology and Carcinogenesis, 610 Medicine & health, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Article, Antibodies, Vaccine Related, 03 medical and health sciences, Young Adult, Meta-Analysis as Topic, Internal medicine, medicine, Humans, In patient, Oncology & Carcinogenesis, Adverse effect, Pneumonitis, Aged, Immunomodulating drugs, business.industry, Evaluation of treatments and therapeutic interventions, medicine.disease, Clinical trial, 030104 developmental biology, Corticosteroid use, Immunization, business, Follow-Up Studies

وصف الملف: application/pdf; 868_Robert_C._et_al._Long-term_safety_of_pembrolizumab_monotherapy_and_relationship_with_clinical_outcome_EJC_2020.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c081e1b4e51d5ab8b097204bced3e77dTest
https://escholarship.org/uc/item/275859csTest

3

Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma

المساهمون: Medical Oncology, Clinical sciences, Laboratory of Molecular and Medical Oncology, Laboratory of Molecullar and Cellular Therapy

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Ipilimumab, Pembrolizumab, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Long term survival, medicine, In patient, business, 030215 immunology, medicine.drug, Advanced melanoma

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2b58ea7696aac607a6b8b94623bd747Test
https://biblio.vub.ac.be/vubir/longterm-survival-fromTest-pembrolizumab-pembro-completion-and-pembro-retreatment-phase-iii-keynote006-in-advanced-melanoma(06384d96-ea38-49d1-a40c-297993de00d7).html

4

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006)

المساهمون: Clinical sciences, Medical Oncology, Laboratory for Medical and Molecular Oncology, Laboratory of Molecullar and Cellular Therapy

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, advanced melanoma, medicine.medical_specialty, Phases of clinical research, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Drug Administration Schedule, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Progression-free survival, ipilimumab, KEYNOTE-006, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, Medicine(all), business.industry, Proportional hazards model, Hazard ratio, Middle Aged, Progression-Free Survival, Clinical trial, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Female, pembrolizumab, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b24205b257822ddbf30cee39b4dc1f9Test
https://biblio.vub.ac.be/vubirTest/(e2696151-46a7-4118-9960-b3e5b06df058).html

5

1080P HORIZON: Final results from a 5-year ambispective study of 705 patients who initiated pembrolizumab for advanced melanoma in the French early access program

المصدر: Annals of Oncology. 32:S895

مصطلحات موضوعية: medicine.medical_specialty, Oncology, Horizon (archaeology), business.industry, General surgery, medicine, Hematology, Pembrolizumab, business, Advanced melanoma

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::ac3d0b71c3636ecb3af6e8951229878eTest
https://doi.org/10.1016/j.annonc.2021.08.1465Test

6

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma

المؤلفون: Jonathan Cebon, Neil Steven, Mark R. Middleton, Darcy A. Hille, Erika Richtig, Céleste Lebbé, Nageatte Ibrahim, Euan Walpole, Caroline Robert, Giuseppe Masucci, Wei Zhou, Wilson H. Miller, Teresa M. Petrella

المصدر: European Journal of Cancer. 86:115-124

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e890ea1bf10f65d9c5dbe680fbd78ba4Test
https://doi.org/10.1016/j.ejca.2017.08.032Test

7

المساهمون: University of Zurich, Schadendorf, Dirk, Medical oncology, CCA - Clinical Therapy Development

المصدر: Schadendorf, D, Dummer, R, Hauschild, A, Robert, C, Hamid, O, Daud, A, van den Eertwegh, A, Cranmer, L, O'Day, S, Puzanov, I, Schachter, J, Blank, C, Salama, A, Loquai, C, Mehnert, J M, Hille, D, Ebbinghaus, S, Kang, S P, Zhou, W & Ribas, A 2016, ' Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma ', European Journal of Cancer, vol. 67, pp. 46-54 . https://doi.org/10.1016/j.ejca.2016.07.018Test
European Journal of Cancer, 67, 46-54. Pergamon

مصطلحات موضوعية: Male, Cancer Research, Skin Neoplasms, Health Status, Health-related quality of life, medicine.medical_treatment, Medizin, Pembrolizumab, Carboplatin, 0302 clinical medicine, Quality of life, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, 030212 general & internal medicine, Melanoma, Aged, 80 and over, 10177 Dermatology Clinic, Middle Aged, Advanced melanoma, Dacarbazine, Oncology, 030220 oncology & carcinogenesis, Female, 2730 Oncology, medicine.drug, Adult, KEYNOTE-002, medicine.medical_specialty, Adolescent, Paclitaxel, 610 Medicine & health, Ipilimumab, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Young Adult, 03 medical and health sciences, Refractory, Internal medicine, Temozolomide, medicine, Humans, Chemotherapy, In patient, Patient Reported Outcome Measures, Aged, Patient-reported outcomes, business.industry, Cancer, EORTC QLQ-C30, medicine.disease, Surgery, Quality of Life, business, Ipilimumab-refractory melanoma